AI-extracted from the 10-Q filed 2026-08-05 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.
Q2 revenue surged 30% to $1.7B driven by BRUKINSA growth of 31%, achieving diluted EPS of $0.16 GAAP and $2.05 per ADS.
Biggest Revenue Drivers
BRUKINSA (zanubrutinib)$1,247.6M+31.4% YoY
Robust demand growth and strong market share gains in U.S., Europe, and Rest of World
TEVIMBRA (tislelizumab)$228.5M+18.1% YoY
Growth from anti-PD-1 antibody commercialization across major markets
Biggest Revenue Drivers
Total revenue: $1,705.1M+29.6% YoY
BRUKINSA (zanubrutinib)$1,247.6M+31.4% YoY
Robust demand growth and strong market share gains in U.S., Europe, and Rest of World
TEVIMBRA (tislelizumab)$228.5M+18.1% YoY
Growth from anti-PD-1 antibody commercialization across major markets
Increased XGEVA sales volume in China under Amgen collaboration
Other revenue$25.3M+91.1% YoY
Royalty revenue from Amgen IMDELLTRA sales and Novartis broad markets agreement
Largest Expense Items
Research and development$612.3M+16.6% YoY
Increased investment in pipeline advancement including BTK CDAC, CDK4, and PRMT5 programs plus higher Amgen co-development costs
Selling, general and administrative$593.2M+10.3% YoY
Continued investment in global commercial expansion primarily in U.S. and Europe
Cost of sales - product$174.5M+6.0% YoY
Production productivity improvements and favorable product mix
Margins: Gross margin expanded to 89.6% for Q2 2026 from 87.4% YoY, driven by higher BRUKINSA proportion of sales mix and manufacturing efficiency gains. Operating margin improved significantly as revenue growth outpaced expense growth, with operating expenses growing only 13.4% while revenue grew 29.6%.
Watch Items from the Filing
Amgen royalty sale liability of $906.3M recorded; repayment depends on future IMDELLTRA royalties through at least 2041 with effective imputed interest rate of 11.0%.
Total debt obligations of $1,073.1M outstanding; $201.1M due within 12 months. Facilities Agreement requires compliance with financial covenants including minimum cash interest coverage ratio of 5.00x and maximum net leverage ratio of 2.50x.
BRUKINSA faces potential generic competition; Zydus filed ANDA in February 2026 with Paragraph IV certifications challenging patents. Company initiated patent infringement litigation but generic composition-of-matter patent remains intact until 2034.
AbbVie litigation alleging misappropriation of trade secrets for BTK degrader program BGB-16673 remains ongoing; motion to dismiss denied May 2026; no trial date scheduled.
Operating cash flow of $664.2M for first six months 2026 versus $307.7M YoY, representing positive operating cash generation trajectory and reduced reliance on external financing.
AI-extracted and verified against SEC EDGAR filing text. Not investment advice.
Sharp ShaliniDirectorGrant or award · Jun 11, 2026
About BeOne Medicines Ltd. (ONC): stock profile, AI score and financials
BeOne Medicines Ltd. (ONC) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ONC at 74.9/100 on a composite quality score built from its SEC filings, placing it at rank #103 of 2,925 stocks — the top 5% of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), BeOne Medicines Ltd. reports quarterly revenue of $1.7B, net income of $237.0M, an operating margin of 19.1%. Top institutional holders of ONC by reported 13-F value include BAKER BROS. ADVISORS, PRIMECAP MANAGEMENT, Capital International Investors, based on the most recent SEC filings. ONC trades on the Nasdaq exchange and files with the SEC under CIK 1651308. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ONC daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for BeOne Medicines Ltd. directly from SEC EDGAR.